{"id":"W4405047635","doi":"10.1182/blood-2024-203274","title":"Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; International Prognostic Scoring System; Anemia; Myelodysplastic syndromes; Quality of life (healthcare); Internal medicine; Population; Physical therapy; Oncology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002941984,0.0006961783,0.0009707433,0.0002029515,0.0002475459,0.0005053027,0.0004814462,0.0005637694,0.003862332],"category_scores_gemma":[0.001037974,0.0002457188,0.0008335154,0.0002140687,0.0004334908,0.0005621679,0.0003148777,0.001970114,0.0006264888],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003959132,"about_ca_system_score_gemma":0.0008059488,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000272988,"about_ca_topic_score_gemma":0.0009199278,"domain_scores_codex":[0.9994714,0.0002928937,0.00003235143,0.00007531119,0.00005858723,0.00006942618],"domain_scores_gemma":[0.9992661,0.0001470295,0.0002361961,0.00006269793,0.00007198829,0.0002160505],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6689314,0.06102618,0.02733946,0.001160089,0.002614164,0.0001390396,0.0003266293,0.001629542,0.03977791,0.0002010942,0.006549059,0.1903055],"study_design_scores_gemma":[0.3610243,0.5622098,0.06380018,0.00007638901,0.001304807,0.0003909749,0.00008532464,0.00111205,0.005957424,0.0002150479,0.003787766,0.00003586569],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948586,0.001645235,0.0003138426,0.0002608186,0.00003334647,0.0008903616,0.001090158,0.00006747971,0.0008402396],"genre_scores_gemma":[0.9921054,0.0009414299,0.001342869,0.0004807155,0.00006349557,0.001505721,0.002019197,0.00001951783,0.001521752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003862332,"threshold_uncertainty_score":0.01555884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05733324950854096,"score_gpt":0.3573693669964672,"score_spread":0.3000361174879262,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}